Rep. Gilbert Ray Cisneros, Jr. Sells Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Arcutis Biotherapeutics stock on December 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Arcutis Biotherapeutics Price Performance

Arcutis Biotherapeutics stock traded down $0.37 during midday trading on Thursday, reaching $26.36. The company’s stock had a trading volume of 1,104,594 shares, compared to its average volume of 1,831,517. The company has a current ratio of 3.50, a quick ratio of 3.28 and a debt-to-equity ratio of 0.68. The stock has a market cap of $3.23 billion, a PE ratio of -73.22 and a beta of 1.71. Arcutis Biotherapeutics, Inc. has a 52 week low of $11.13 and a 52 week high of $31.77. The business has a 50-day moving average price of $28.40 and a 200-day moving average price of $21.22.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16. The company had revenue of $99.22 million for the quarter, compared to the consensus estimate of $86.69 million. Arcutis Biotherapeutics had a negative net margin of 13.94% and a negative return on equity of 29.69%. On average, sell-side analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current year.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Institutional investors have recently modified their holdings of the company. Johnson Investment Counsel Inc. bought a new position in shares of Arcutis Biotherapeutics in the 3rd quarter worth about $30,000. PNC Financial Services Group Inc. increased its holdings in Arcutis Biotherapeutics by 10.2% in the second quarter. PNC Financial Services Group Inc. now owns 8,828 shares of the company’s stock worth $124,000 after purchasing an additional 820 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Arcutis Biotherapeutics by 1,291.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 7,067 shares of the company’s stock worth $124,000 after buying an additional 6,559 shares in the last quarter. Atlas Wealth LLC bought a new position in shares of Arcutis Biotherapeutics during the 2nd quarter worth approximately $138,000. Finally, Quantbot Technologies LP bought a new stake in shares of Arcutis Biotherapeutics in the 2nd quarter valued at $145,000.

Insider Activity at Arcutis Biotherapeutics

In related news, insider Todd Watanabe sold 48,945 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $30.36, for a total transaction of $1,485,970.20. Following the transaction, the insider directly owned 740,537 shares of the company’s stock, valued at approximately $22,482,703.32. This represents a 6.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Neha Krishnamohan sold 40,504 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $23.20, for a total value of $939,692.80. Following the completion of the transaction, the director owned 22,123 shares in the company, valued at approximately $513,253.60. The trade was a 64.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 293,912 shares of company stock worth $7,885,305 over the last ninety days. 9.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ARQT shares. The Goldman Sachs Group upped their price target on shares of Arcutis Biotherapeutics from $19.00 to $29.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Needham & Company LLC upped their target price on Arcutis Biotherapeutics from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Zacks Research lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Arcutis Biotherapeutics in a report on Wednesday, October 29th. Finally, Mizuho raised their price objective on shares of Arcutis Biotherapeutics from $32.00 to $37.00 and gave the company an “outperform” rating in a report on Friday, November 28th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.